DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.59 -0.17%

-$0.01 today

Market cap
$463.49M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.21M

Average 0.19M

DMAC Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

DiaMedica Therapeutics Inc.NASDAQ: DMAC

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables remains negative

Q1 FY2026 net receivables was $0, compared with $253K a year earlier. Over 3 fiscal years it compounded at +46.5% a year.

Context

  • Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.7 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$258K+9.3% YoY
Year agoMar 2025
$253K-100.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+9.3%——
3-year CAGR+46.5%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
258K USD
Year-over-year change
+9.3%

Net Receivables vs competitors

How DMAC compares with its peers on the latest reported figures

  • DMAC's Mar 2026 net receivables of $0 is the 6th highest of the 7 companies compared; the peer median is $2.48M.
  • Its year-over-year change of -100.0% is the lowest of 4, against a peer median of +1.6%.
  • Net receivables amounts to 0.0% of total assets for DMAC, versus a peer median of 0.3%.
DMAC Competitors Peer median
Net Receivables for DMAC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AKBAAkebia Therapeutics, Inc.Mar 2026$62.54M +1.6%+5.3%17.3%
MAZEMaze Therapeutics, Inc.Mar 2026$20M ——4.8%
DNLIDenali Therapeutics Inc.Jun 2026$3.93M —-38.3%0.3%
PROKProKidney Corp.Mar 2026$1.03M -41.1%—0.4%
BIOABioAge Labs, Inc.Mar 2026$709K +96.4%—0.2%
DMACDiaMedica Therapeutics Inc.Mar 2026$0 -100.0%+46.5%0.0%
UNCYUnicycive Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding DMAC) $2.48M+1.6%-16.5%0.3%

Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents4.71M4.73M4.54M3.03M15.65M
Short-term Investments40.41M28.77M48.35M41.12M44.24M
Net Receivables082K369K236K258K
Inventory00000
Other Current Assets243K00227K481K
Total Current Assets45.44M33.84M53.68M44.61M60.63M
Property, Plant & Equipment (Net)112K560K485K427K342K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0001.31M400K
Total Non-current Assets112K560K485K1.74M742K
Total Assets45.55M34.4M54.16M46.35M61.37M
Account Payables509K734K926K940K1.48M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities484K667K766K1.06M1.38M
Total Current Liabilities1.52M2.17M2.79M5.39M5.13M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities3K400K317K237K128K
Total Liabilities1.53M2.57M3.1M5.63M5.26M
Common Stock00000
Retained Earnings(82.5M)(96.18M)(115.56M)(140M)(172.77M)
Accumulated OCI(51K)(74K)6K23K50K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity44.02M31.83M51.06M40.72M56.11M
Total Debt52K469K400K340K240K
Net Debt(4.66M)(4.26M)(4.14M)(2.69M)(15.41M)

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Intrinsic Alpha fair value

Locked

Current Price

$8.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.